Effects of Fenofibrate Therapy in Diabetic Nephropathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT03869931

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03869931
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Singapore (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03869931. Allocation not applicable; no masking; primary purpose treatment. Start 2019-03-08 (actual); primary completion 2021-04-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Fenofibrate Therapy in Diabetic Nephropathy
Condition
Diabetes Mellitus
Condition
Diabetic Nephropathies
Intervention (Drug)
Fenofibrate
Lead sponsor
Singapore General Hospital (class: other)
Collaborator
National Medical Research Council (NMRC), Singapore (class: other government)

Record details

Record id
cardio:ct-nct03869931
Content hash
a73eedab1b1895e42b1c23c79156c1087c8bcc3608318360735cd769daa8fbdb